Pacira (PCRX) Q2 Revenue Rises 1.7%
Pacira BioSciences (NASDAQ:PCRX) is a specialty pharmaceutical company known for its non-opioid pain management products. On August 5, 2025, it reported financial results for the quarter. The headline results showed non-GAAP earnings per share of $0.74, beating analyst consensus by 4.2% (non-GAAP), while revenue (GAAP) came in at $181.1 million, missing GAAP revenue expectations by 1.1%. Compared to a year ago, GAAP revenue rose 1.7%, with modest growth in the flagship EXPAREL product and slight gains for ZILRETTA net product sales. The quarter saw higher operating expenses (GAAP) and a narrowed revenue guidance range for the year. Overall performance reflected progress in manufacturing and innovation, but top-line growth (GAAP revenue) remained subdued.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Pacira BioSciences develops and markets non-opioid pain products for surgical and musculoskeletal conditions. Its key offerings include EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain; ZILRETTA, an injectable extended-release steroid for osteoarthritis knee pain; and iovera°, a device for nerve block treatments. EXPAREL accounts for most of Pacira’s revenue, making its continued adoption essential for the company’s results.
Source Fool.com
